European agency prepares for new rules to improve drug safetyBMJ 2012; 344 doi: http://dx.doi.org/10.1136/bmj.e955 (Published 07 February 2012) Cite this as: BMJ 2012;344:e955
- Rory Watson
The London based European Medicines Agency is stepping up its preparations for new EU pharmacovigilance legislation that will come into force in July and will introduce the biggest change in the legal framework since the agency was established in 1995.
Among other changes, patients in Europe will for the first time be given the right to report suspected adverse reactions to national drug authorities, a right that already exists in the United Kingdom and some other European countries.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial